6-Thioguanine blocks SARS-CoV-2 replication by inhibition of PLpro protease activities

A recently emerged betacoronavirus, SARS-CoV-2, has led to a global health crisis that calls for the identification of effective therapeutics for COVID-19 disease. Coronavirus papain-like protease (PLpro) is an attractive drug target as it is essential for viral polyprotein cleavage and for deconjug...

Descripción completa

Detalles Bibliográficos
Autores principales: Swaim, Caleb D., Perng, Yi-Chieh, Zhao, Xu, Canadeo, Larissa A., Harastani, Houda H., Darling, Tamarand L., Boon, Adrianus C. M., Lenschow, Deborah J., Huibregtse, Jon M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7337375/
https://www.ncbi.nlm.nih.gov/pubmed/32637945
http://dx.doi.org/10.1101/2020.07.01.183020
Descripción
Sumario:A recently emerged betacoronavirus, SARS-CoV-2, has led to a global health crisis that calls for the identification of effective therapeutics for COVID-19 disease. Coronavirus papain-like protease (PLpro) is an attractive drug target as it is essential for viral polyprotein cleavage and for deconjugation of ISG15, an antiviral ubiquitin-like protein. We show here that 6-Thioguanine (6-TG) inhibits SARS-CoV-2 PLpro-catalyzed viral polyprotein cleavage and ISG15 deconjugation in cells and inhibits replication of SARS-CoV-2 in Vero-E6 cells and Calu3 cells at submicromolar levels. As a well-characterized FDA-approved orally delivered drug, 6-TG represents a promising therapeutic for COVID-19 and other emerging coronaviruses.

Ejemplares similares